EMAIL THIS PAGE TO A FRIEND

The American journal of cardiology

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).


PMID 23290925

Abstract

Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF. Compared to β(1)-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16). In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients. Additionally, carvedilol significantly reduced all-cause mortality compared with β(1)-selective BBs in AMI patients using the fixed-effects model but not using the random-effects model.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M5391
(±)-Metoprolol (+)-tartrate salt, ≥98% (titration), powder
C30H50N2O6 · C4H6O6
A-072
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
C14H22N2O3
Y0000877
Bisoprolol for peak identification, European Pharmacopoeia (EP) Reference Standard
C18H31NO4 · .5C4H4O4
Y0000813
Bisoprolol for system suitability, European Pharmacopoeia (EP) Reference Standard
C18H31NO4 · .5C4H4O4
Y0000812
Bisoprolol fumarate, European Pharmacopoeia (EP) Reference Standard
C18H31NO4 · .5C4H4O4
B2185
Bisoprolol hemifumarate salt, ≥98% (HPLC), solid
C18H31NO4 · .5C4H4O4
C3993
Carvedilol, ≥98% (HPLC), solid
C24H26N2O4
1096622
Carvedilol, United States Pharmacopeia (USP) Reference Standard
C24H26N2O4
PHR1265
Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
C24H26N2O4
Y0001427
Carvedilol, European Pharmacopoeia (EP) Reference Standard
C24H26N2O4
Y0001426
Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H26N2O4
M1830000
Metoprolol tartrate, European Pharmacopoeia (EP) Reference Standard
C30H50N2O6 · C4H6O6
PHR1076
Metoprolol Tartrate, Pharmaceutical Secondary Standard; Certified Reference Material
C30H50N2O6 · C4H6O6
M-123
Metoprolol tartrate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
C15H25NO3 · 0.5 C4H6O6